These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 32212804

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H, Matsushita Y, Machida R, Yamasaki K, Hata N, Ohno M, Yamaguchi S, Sasayama T, Tanaka S, Higuchi F, Iuchi T, Saito K, Kanamori M, Matsuda KI, Miyake Y, Tamura K, Tamai S, Nakamura T, Uda T, Okita Y, Fukai J, Sakamoto D, Hattori Y, Pareira ES, Hatae R, Ishi Y, Miyakita Y, Tanaka K, Takayanagi S, Otani R, Sakaida T, Kobayashi K, Saito R, Kurozumi K, Shofuda T, Nonaka M, Suzuki H, Shibuya M, Komori T, Sasaki H, Mizoguchi M, Kishima H, Nakada M, Sonoda Y, Tominaga T, Nagane M, Nishikawa R, Kanemura Y, Kuchiba A, Narita Y, Ichimura K.
    Acta Neuropathol Commun; 2020 Nov 23; 8(1):201. PubMed ID: 33228806
    [Abstract] [Full Text] [Related]

  • 3. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR, Dietrich J, Atkins KM, Oh KS, Loeffler JS, Shih HA.
    Cancer Med; 2020 Jan 23; 9(1):3-11. PubMed ID: 31701682
    [Abstract] [Full Text] [Related]

  • 4. Radio-chemotherapy improves survival in IDH-mutant, 1p/19q non-codeleted secondary high-grade astrocytoma patients.
    Juratli TA, Lautenschläger T, Geiger KD, Pinzer T, Krause M, Schackert G, Krex D.
    J Neurooncol; 2015 Sep 23; 124(2):197-205. PubMed ID: 26033545
    [Abstract] [Full Text] [Related]

  • 5. Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.
    Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.
    J Neurooncol; 2013 Aug 23; 114(1):85-91. PubMed ID: 23681562
    [Abstract] [Full Text] [Related]

  • 6. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
    Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C.
    Oncotarget; 2015 Oct 06; 6(30):30295-305. PubMed ID: 26210286
    [Abstract] [Full Text] [Related]

  • 7. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK, Simpson JR, Robinson CG, DeWees TA, Tran DD, Linette G, Chicoine MR, Dacey RG, Rich KM, Dowling JL, Leuthardt EC, Zipfel GJ, Kim AH, Huang J.
    Int J Radiat Oncol Biol Phys; 2015 Feb 01; 91(2):268-76. PubMed ID: 25636755
    [Abstract] [Full Text] [Related]

  • 8. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of IDH1-Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas.
    Park YW, Han K, Ahn SS, Choi YS, Chang JH, Kim SH, Kang SG, Kim EH, Lee SK.
    AJNR Am J Neuroradiol; 2018 Apr 01; 39(4):693-698. PubMed ID: 29519794
    [Abstract] [Full Text] [Related]

  • 9. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
    Habiba U, Sugino H, Yordanova R, Ise K, Tanei ZI, Ishida Y, Tanikawa S, Terasaka S, Sato KI, Kamoshima Y, Katoh M, Nagane M, Shibahara J, Tsuda M, Tanaka S.
    Acta Neuropathol Commun; 2021 May 21; 9(1):95. PubMed ID: 34020723
    [Abstract] [Full Text] [Related]

  • 10. Prediction of IDH1-Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas.
    Park YW, Han K, Ahn SS, Bae S, Choi YS, Chang JH, Kim SH, Kang SG, Lee SK.
    AJNR Am J Neuroradiol; 2018 Jan 21; 39(1):37-42. PubMed ID: 29122763
    [Abstract] [Full Text] [Related]

  • 11. MRI features predict survival and molecular markers in diffuse lower-grade gliomas.
    Zhou H, Vallières M, Bai HX, Su C, Tang H, Oldridge D, Zhang Z, Xiao B, Liao W, Tao Y, Zhou J, Zhang P, Yang L.
    Neuro Oncol; 2017 Jun 01; 19(6):862-870. PubMed ID: 28339588
    [Abstract] [Full Text] [Related]

  • 12. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.
    Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B.
    Turk Neurosurg; 2017 Jun 01; 27(5):682-689. PubMed ID: 27651340
    [Abstract] [Full Text] [Related]

  • 13. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
    Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D, POLA Network.
    Neuro Oncol; 2019 Dec 17; 21(12):1519-1528. PubMed ID: 31832685
    [Abstract] [Full Text] [Related]

  • 14. Impact of 1p/19q codeletion status on extent of resection in WHO grade II glioma: Insights from a national cancer registry.
    Lu VM, Alvi MA, Bydon M, Quinones-Hinojosa A, Chaichana KL.
    Clin Neurol Neurosurg; 2019 Jul 17; 182():32-36. PubMed ID: 31063969
    [Abstract] [Full Text] [Related]

  • 15. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas.
    Sabha N, Knobbe CB, Maganti M, Al Omar S, Bernstein M, Cairns R, Çako B, von Deimling A, Capper D, Mak TW, Kiehl TR, Carvalho P, Garrett E, Perry A, Zadeh G, Guha A, Sidney Croul.
    Neuro Oncol; 2014 Jul 17; 16(7):914-23. PubMed ID: 24470545
    [Abstract] [Full Text] [Related]

  • 16. Role of 1p/19q Codeletion in Diffuse Low-grade Glioma Tumour Prognosis.
    Familiari P, Lapolla P, Picotti V, Palmieri M, Pesce A, Carosi G, Relucenti M, Nottola S, Gianno F, Minasi S, Antonelli M, Frati A, Santoro A, D'Andrea G, Bruzzaniti P, LA Pira B.
    Anticancer Res; 2023 Jun 17; 43(6):2659-2670. PubMed ID: 37247932
    [Abstract] [Full Text] [Related]

  • 17. 18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma.
    Cicone F, Carideo L, Scaringi C, Arcella A, Giangaspero F, Scopinaro F, Minniti G.
    Ann Nucl Med; 2019 Apr 17; 33(4):295-302. PubMed ID: 30607877
    [Abstract] [Full Text] [Related]

  • 18. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A.
    J Clin Oncol; 2020 Oct 10; 38(29):3407-3417. PubMed ID: 32706640
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC, Lo CM, Wang SH, Su EC.
    BMC Bioinformatics; 2019 Dec 24; 20(Suppl 19):659. PubMed ID: 31870275
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.